VEGF gene polymorphisms in Iranian patients with intracranial glioblastoma.


Journal

Journal of neurosurgical sciences
ISSN: 1827-1855
Titre abrégé: J Neurosurg Sci
Pays: Italy
ID NLM: 0432557

Informations de publication

Date de publication:
18 Jan 2023
Historique:
entrez: 18 1 2023
pubmed: 19 1 2023
medline: 19 1 2023
Statut: aheadofprint

Résumé

Glioblastoma is one of the most common malignant brain tumors in adults with poor prognosis. Neovascularization is one of the characteristics of these tumors, which is associated with overexpression of vascular endothelial growth factor (VEGF). Accordingly, single nucleotide polymorphisms of this gene could play an important role in structural and functional alterations leading to overexpression of this gene in GBM. A total number of 49 patients with GBM and 50 healthy controls were included in the current study. The Genomic DNA was extracted from brain tumor/tissue samples, and after purification assessment, the alleles, and genotypes of rs3025039 and rs2010963 polymorphisms of the VEGF gene were investigated using T-ARMS-PCR. The "T" allele of rs3025039 was 2.79 times more frequent in GBM patients compared to controls (P=0.01). Moreover, the "CT" genotype was 2.83 times more common among patients (P=0.015), while the "CC" was more frequent in controls (P=0.009). The mean overall survival was significantly different between three genotypes of rs3025039, with the longest survival time in "CT" genotype (15.10±5.21, P=0.041). Besides, rs2010963, was significantly associated with GBM occurrence, with the "G" allele being 1.96 times more frequent in patients (P=0.01), as well as the "GG" genotype, which was 7.87 times more common in patients (P<0.001). Polymorphisms of VEGF could potentially play a role in pathogenesis of GBM, as the allele and genotype distributions of rs3025039 and rs2010963 SNPs were significantly associated with GBM occurrence.

Sections du résumé

BACKGROUND BACKGROUND
Glioblastoma is one of the most common malignant brain tumors in adults with poor prognosis. Neovascularization is one of the characteristics of these tumors, which is associated with overexpression of vascular endothelial growth factor (VEGF). Accordingly, single nucleotide polymorphisms of this gene could play an important role in structural and functional alterations leading to overexpression of this gene in GBM.
METHODS METHODS
A total number of 49 patients with GBM and 50 healthy controls were included in the current study. The Genomic DNA was extracted from brain tumor/tissue samples, and after purification assessment, the alleles, and genotypes of rs3025039 and rs2010963 polymorphisms of the VEGF gene were investigated using T-ARMS-PCR.
RESULTS RESULTS
The "T" allele of rs3025039 was 2.79 times more frequent in GBM patients compared to controls (P=0.01). Moreover, the "CT" genotype was 2.83 times more common among patients (P=0.015), while the "CC" was more frequent in controls (P=0.009). The mean overall survival was significantly different between three genotypes of rs3025039, with the longest survival time in "CT" genotype (15.10±5.21, P=0.041). Besides, rs2010963, was significantly associated with GBM occurrence, with the "G" allele being 1.96 times more frequent in patients (P=0.01), as well as the "GG" genotype, which was 7.87 times more common in patients (P<0.001).
CONCLUSIONS CONCLUSIONS
Polymorphisms of VEGF could potentially play a role in pathogenesis of GBM, as the allele and genotype distributions of rs3025039 and rs2010963 SNPs were significantly associated with GBM occurrence.

Identifiants

pubmed: 36651322
pii: S0390-5616.22.05832-5
doi: 10.23736/S0390-5616.22.05832-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Sara Hanaei (S)

Department of Neurosurgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Hanieh Mojtahedi (H)

Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Mohamad Namvar (M)

Department of Neurosurgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

Arad Iranmehr (A)

Department of Neurosurgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

Reyhaneh Safaei (R)

Department of Pathology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.

Azadehsadat Razavi (A)

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Marzie Esmaeili (M)

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Sadr (M)

Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Arezou Rezaei (A)

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Edalatfar (M)

Department of Neurosurgery, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hamidreza Khayat Kashani (H)

Department of Neurosurgery, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mohsen Sadeghi-Naini (M)

Department of Neurosurgery, Lorestan University of Medical Sciences, Khorram Abad, Iran.

Farzaneh Darbeheshti (F)

School of Medicine, Department of Genetics, Tehran University of Medical Sciences, Tehran, Iran.

Jaber Gharehdaghi (J)

Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran.

Mehdi Forouzesh (M)

Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran.

Abdolali Ebrahimi (A)

School of Medicine, Department of Pathology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Nima Rezaei (N)

Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran - rezaei_nima@tums.ac.ir.
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
School of Medicine, Department of Pathology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
School of Medicine, Department of Immunology, Tehran University of Medical Sciences, Tehran, Iran.

Classifications MeSH